EA201891354A1 - EZH2 INHIBITORS AND METHODS OF THEIR APPLICATION - Google Patents

EZH2 INHIBITORS AND METHODS OF THEIR APPLICATION

Info

Publication number
EA201891354A1
EA201891354A1 EA201891354A EA201891354A EA201891354A1 EA 201891354 A1 EA201891354 A1 EA 201891354A1 EA 201891354 A EA201891354 A EA 201891354A EA 201891354 A EA201891354 A EA 201891354A EA 201891354 A1 EA201891354 A1 EA 201891354A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
application
subject
ezh2 inhibitors
ezh2
Prior art date
Application number
EA201891354A
Other languages
Russian (ru)
Inventor
Стефен Блейкмор
Скотт Ричард Дейгл
Original Assignee
Эпизайм, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эпизайм, Инк. filed Critical Эпизайм, Инк.
Priority claimed from PCT/US2016/065447 external-priority patent/WO2017100362A2/en
Publication of EA201891354A1 publication Critical patent/EA201891354A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Abstract

В изобретении предусмотрен способ лечения рака у нуждающегося в этом субъекта, включающий введение субъекту терапевтически эффективного количества ингибитора энхансера гомолога 2 zeste-белка (EZH2). В определенных вариантах осуществления данного способа у субъекта имеется одна или несколько мутаций в одной или нескольких последовательностях, кодирующих гены, перечисленные в табл. 1-9, 17-19 и/или на фиг. 19-22.The invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an enhancer inhibitor of the zeste protein homolog 2 (EZH2). In certain embodiments of this method, the subject has one or more mutations in one or more of the sequences encoding the genes listed in Table. 1-9, 17-19 and / or in FIG. 19-22.

EA201891354A 2016-10-17 2016-12-07 EZH2 INHIBITORS AND METHODS OF THEIR APPLICATION EA201891354A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662409320P 2016-10-17 2016-10-17
PCT/US2016/065447 WO2017100362A2 (en) 2015-12-07 2016-12-07 Inhibitors of ezh2 and methods of use thereof

Publications (1)

Publication Number Publication Date
EA201891354A1 true EA201891354A1 (en) 2019-06-28

Family

ID=66998689

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891354A EA201891354A1 (en) 2016-10-17 2016-12-07 EZH2 INHIBITORS AND METHODS OF THEIR APPLICATION

Country Status (1)

Country Link
EA (1) EA201891354A1 (en)

Similar Documents

Publication Publication Date Title
EA202092590A1 (en) PYRIDAZINONES AS PARP7 INHIBITORS
WO2017100362A3 (en) Inhibitors of ezh2 and methods of use thereof
EA201992220A1 (en) COMBINED THERAPY FOR TREATMENT OR PREVENTION OF TUMORS
EA201792229A1 (en) Bromodomain inhibitors
MX2019007243A (en) Ectonucleotidase inhibitors and methods of use thereof.
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
EA201890567A1 (en) CANCER TREATMENT METHOD
EA201692285A1 (en) EZH2 INHIBITORS FOR TREATING LYMPHOMA
BR112019002331A2 (en) anti-siglec-7 antibodies for cancer treatment and methods of obtaining them
EA201791095A1 (en) CANCER TREATMENT METHOD
EA201890801A1 (en) METHOD OF TREATMENT OF MALIGNANT WORK OVARIAN TUMOR (MRTO) / MICRO-CELLULAR CANCER OF OVARIES OF HYPERCALCEMIC TYPE (SCCOHT) WITH THE HELP OF EZH2 INHIBITOR
EA201592068A1 (en) INHANSER INHIBITORS ZESTE HOMOLOGIST 2
EA201992137A1 (en) Pyrimidopyrimidinones as Wee-1 Kinase Inhibitors
EA201890878A1 (en) METHOD OF TREATMENT OF MEDDALLOBLASTOMES USING EZH2 INHIBITOR
EA201791736A1 (en) COMBINED THERAPY FOR CANCER TREATMENT
EA202090572A1 (en) INHIBITORS OF RHO-ASSOCIATED SUPERSPIRAL PROTEIN KINASE
EA201892287A1 (en) PHARMACEUTICAL COMBINATIONS FOR CANCER TREATMENT
EA201792580A1 (en) IDO INHIBITORS
EA201792641A1 (en) IGFBP3 / TMEM219 AXIS INHIBITOR AND DIABETES
EA202090306A1 (en) INHIBITORS OF RHO-ASSOCIATED CONTAINING SUPERSPIRAL PROTEINKINASE
EA201990508A1 (en) ACTIVITY INHIBITION Olig2
EA202090266A1 (en) MPO INHIBITORS FOR MEDICAL USE
MX2020012782A (en) Ccr5 inhibitor for use in treating cancer.
EA201891354A1 (en) EZH2 INHIBITORS AND METHODS OF THEIR APPLICATION
EA202190125A1 (en) PYRIDOPYRIMIDINONE DERIVATIVES FOR USE AS Axl INHIBITORS